General Updates

October 13, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, (“Listing Regulations”) - Update on Acquisition by PathLabs Unifiers Private Limited, a Wholly Owned Subsidiary Dear Sir/ Madam, With reference to the captioned subject and in continuation of our earlier intimation dated October 12, 2026, regarding update on further investment by Dr. Lal PathLabs Limited ("the Company") in PathLabs Unifiers Private Limited ("PUPL"), a Wholly Owned Subsidiary of the Company, we wish to inform you that PUPL has acquired the remaining 30% equity stake in Centrapath Labs Private Limited ("CPL"), a Subsidiary of PUPL, on October 13, 2026. Pursuant to the aforesaid acquisition, CPL has become a Wholly Owned Subsidiary of PUPL. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, is enclosed herewith as “Annexure – A”. We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl: as above Annexure-A DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023: SN Particulars Acquisition of Company 1 Name of the target entity, details in brief Centrapath Labs Private Limited (“CPL”) such as size, turnover etc. Turnover: FY 2026: 20.5 Crores FY 2025: 23.7 Crores FY 2024: 20.8 Crores 2 Whether the acquisition would fall within No, the transaction is not a related party related party transaction(s) and whether transaction. the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” 3 Industry to which the entity being Healthcare/ Diagnostics Services acquired belongs 4 Objects and impact of acquisition The investment pertains to the acquisition by (including but not limited to, disclosure PathLabs Unifiers Private Limited (“PUPL”) of of reasons for acquisition of target the remaining 30% equity stake in its entity, if its business is outside the main subsidiary, CPL. Consequently, CPL has line of business of the listed entity) become a Wholly Owned Subsidiary of PUPL. 5 Brief details of any governmental or Not Applicable regulatory approvals required for the acquisition 6 Indicative time period for completion of Completed the acquisition 7 Consideration - whether cash Cash Consideration consideration or share swap or any other form and details of the same 8 Cost of acquisition and/or the price at Acquired 30% equity shareholding of CPL at which the shares are acquired INR 1608.352 per share 9 Percentage of shareholding / control CPL has now become a Wholly Owned acquired and / or number of shares Subsidiary of the PUPL. acquired 10 Brief background about the entity CPL was incorporated on July 23, 2019, in acquired in terms of products/line of Indore, Madhya Pradesh and is engaged in business acquired, date of business of providing Healthcare/ Diagnostics incorporation, history of last 3 years Services. turnover, country in which the acquired entity has presence and any other Turnover: As mentioned in Clause 1 above significant information (in brief)